We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| KraneShares Artificial Intelligence ETF | NASDAQ:AGIX | NASDAQ | Exchange Traded Fund |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.10 | 0.35% | 28.34 | 24.18 | 42.42 | 28.63 | 28.23 | 28.54 | 6,881 | 21:30:00 |
From Jan 2020 to Jan 2025
ATLANTA, GA , a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it will release its second quarter 2008 financial results on Tuesday, August 5, 2008 before the U.S. financial markets open.
Conference Call and Webcast Information
Company officials will discuss second quarter 2008 financial results via conference call and webcast on Tuesday, August 5, 2008, at 9:00 a.m. EDT. Participants may access the live conference call by dialing 877-407-8031 (domestic) or 201-689-8031 (international). To access the webcast, please visit the AtheroGenics Investor Relations website at www.atherogenics.com. A replay of the conference call will be accessible approximately one hour after the conclusion of the call by dialing 877-660-6853 (domestic) or 201-612-7415 (international), account number 286, conference ID number 292374. A replay of the webcast will be archived on the Company's website until November 6, 2008.
About AtheroGenics
AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease (atherosclerosis). The Company's lead product candidate, AGI-1067, is a novel antioxidant and anti-inflammatory agent that is currently being evaluated in a Phase III registration study called ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study) as an oral treatment for Type 2 diabetes. In addition, the Company has other clinical and preclinical anti-inflammatory compounds, including AGI-1096, an oral agent for the prevention of organ transplant rejection. For more information about AtheroGenics, please visit http://www.atherogenics.com.
CONTACTS: AtheroGenics, Inc. Mark P. Colonnese Executive Vice President 678-336-2511 Email Contact Media Inquiries Jayme Maniatis / Dana Conti Schwartz Communications, Inc. 781-684-0770 Email Contact Investor Inquiries Lilian Stern Stern Investor Relations, Inc. 212-362-1200 Email Contact
1 Year KraneShares Artificial I... Chart |
1 Month KraneShares Artificial I... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
